Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Functional Restoration and Integrative Therapies in Service Members With Neuromusculoskeletal Injury

10 de octubre de 2022 actualizado por: Ardith Doorenbos, University of Washington

Determinants of the Optimal Dose and Sequence of Functional Restoration and Integrative Therapies in Service Members With Neuromusculoskeletal Injury

This study will (1) compare the effectiveness of standard rehabilitative pain care with complementary and integrative pain therapies; (2) identify subgroups of patients who do and do not respond to the intervention(s); (3) determine the most effective sequencing of the interventions; and (4) determine factors associated with treatment response that can be implemented to support clinical decision-making.

Descripción general del estudio

Descripción detallada

Objectives and Rationale. Pain due to neuromusculoskeletal injuries is a leading cause of disability among active duty military Service members. The injury rate is significant with 628 neuromusculoskeletal injuries per 1000 person-years among active duty military Service members. Neuromusculoskeletal injuries include amputations following battlefield trauma, repetitive motion injuries related to equipment use or weight-bearing postures, and even injuries or strains incurred during off-duty pursuits. Regardless of cause, the effects on both individual Service members and military readiness are significant: Only 13% of Service members being treated primarily for pain ever return to the field.

The Department of Defense (DoD) has recently expanded its capacity to provide both functional restoration (FR) and complementary and integrative medicine (CIM) therapies for neuromusculoskeletal injury, pain, and disability. The proposed research aims to determine the most effective treatment combination, sequence, and duration of standard rehabilitative care (SRC), such as physical and occupational therapy in combination with cognitive behavioral therapy and CIM therapies, such as acupuncture and chiropractic, for Service members preparing to enroll in an intensive FR program that is currently the DoD-recommended treatment. In addition, this study aims to identify ways to predict in advance which patients will respond best to which therapeutic regimens.

Potential Impact. This research has the potential to determine which patients are most likely to benefit from the non-medication pain therapies currently available in all Army Interdisciplinary Pain Management Centers (IPMC) and how these therapies can most effectively be combined to achieve the greatest improvements in pain impact, quality of life and ability to return to duty following injury.

Patients Who Will Benefit. This study will involve active duty Service members referred to an Army IPMC. The results will be shared with other Military Health System (MHS) and Veterans Health Administration (VHA) pain management centers so that active duty Service members and veterans across United States may benefit from a treatment approach that is tailored to their individual characteristics. It is anticipated that the knowledge gained through this research will be applicable to family members of Service members and veterans and will ultimately lead to expansion of TRICARE benefits to include CIM therapies.

Potential Clinical Applications, Benefits, and Risks. This research will assist providers in determining when to refer their patients with neuromusculoskeletal pain for SRC and/or CIM therapies prior to FR. It will assist IPMCs in developing treatment plans tailored to the needs of each patient. Service members and veterans will benefit by being referred for these approaches when appropriate during the course of disabling chronic pain conditions. Ultimately, it is hoped that decision tools can be imbedded in the electronic medical record to guide health care providers to consider referral for these therapies in patients who may benefit. This study will advance our ability to effectively tailor therapies for rehabilitation from neuromusculoskeletal pain for different patients to yield the greatest benefit in physical function and quality of life. The risks of these interventions are minimal; Service members may experience general muscle soreness for the first week or so of increased physical activity, but this typically resolves.

Projected Timeline. This research will determine the optimal combination, sequence, and duration of therapies. It is expected that some active duty Service members could see improvements in function and quality of life within three weeks, but others may require up to six weeks to experience meaningful improvement.

Benefit to Military Personnel. This research will benefit Service members experiencing pain due to neuromusculoskeletal injury. It will identify ways to direct them to the therapies most likely to yield meaningful improvements in function and quality of life, and thus facilitate their return to duty. The recommendations from this study will be shared with pain management centers throughout the DoD, VHA; and, we hope, eventually to TRICARE members.

Tipo de estudio

Intervencionista

Inscripción (Anticipado)

280

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Washington
      • Tacoma, Washington, Estados Unidos, 98431
        • Madigan Army Medical Center

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 70 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Active duty service members
  • Neuromusculoskeletal or neuropathic pain ≥ 3-months duration
  • Pain of sufficient severity to bring about dysfunction in daily social, vocational, and/or interpersonal activities

Exclusion Criteria:

  • Major surgeries within past 6 months or planned within next 6 months
  • Unstable psychological disorders
  • Active substance use disorder

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Complementary and Integrative Therapies
Chiropractic, Acupuncture, Yoga, Biofeedback (if indicated), and Foam roller instruction
Intervention time period is 3 - 6 weeks.
Comparador activo: Standard Rehabilitative Care
Cognitive Behavioral Therapy (CBT) 60-minute orientation, CBT psychoeducation group, and Physical therapy/occupational therapy
Intervention time period is 3 - 6 weeks.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change from Baseline Pain Intensity
Periodo de tiempo: 3 months
Pain Intensity 10-pt Numeric Rating Scale
3 months
Change from Baseline Pain Impact
Periodo de tiempo: 3 months
Aggregate score calculated from Defense and Veterans Pain Rating Scale (DVPRS)
3 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Depression
Periodo de tiempo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Patient Reported Outcome Measurement Information System
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Anxiety
Periodo de tiempo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Patient Reported Outcome Measurement Information System
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Emotional Distress - Anger
Periodo de tiempo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Patient Reported Outcome Measurement Information System
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Sleep Disturbance
Periodo de tiempo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Patient Reported Outcome Measurement Information System
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Fatigue
Periodo de tiempo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Patient Reported Outcome Measurement Information System
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
PTSD
Periodo de tiempo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Primary Care PTSD Screen
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Patient Activation Measure
Periodo de tiempo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
A 22-item survey that addresses four stages of patient activation: (1) believing the patient role is important, (2) having the confidence and knowledge necessary to take action, (3) actually taking action to maintain and improve one's health, and (4) staying the course even under stress. Patients are asked to agree or not to agree with each of the 22 items.
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Drug Use
Periodo de tiempo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Drug Use Questionnaire
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Pain Catastrophizing
Periodo de tiempo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Pain Catastrophizing Scale
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Kinesiophobia
Periodo de tiempo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Tampa Scale for Kinesiophobia
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Pain Self-Efficacy
Periodo de tiempo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Pain Self Efficacy Questionnaire
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Chronic Pain Acceptance
Periodo de tiempo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Chronic Pain Acceptance Questionnaire
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Functional Capacity
Periodo de tiempo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Roland-Morris Disability Questionnaire and Canadian Occupational Performance Measure
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Opioid Utilization
Periodo de tiempo: baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Opioid Utilization Screener
baseline, 3 weeks, 6 weeks, 9 weeks, 3 months, 6 months
Cortisol
Periodo de tiempo: baseline, 6 weeks
Salivary Cortisol
baseline, 6 weeks
Oxidative Stress
Periodo de tiempo: baseline, 6 weeks
Urine Sample
baseline, 6 weeks
Genomic DNA
Periodo de tiempo: baseline
Buccal Sample
baseline
Army Physical Fitness Test (APFT)
Periodo de tiempo: baseline, 6 weeks, 3 months, 6 months
Passing scores of 60 on all 3 components (push-ups, sit-ups, 2-mile run) of the APFT will be operationalized as "force-readiness".
baseline, 6 weeks, 3 months, 6 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Ardith Z Doorenbos, RN, PhD, University of Washington

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

15 de junio de 2018

Finalización primaria (Anticipado)

30 de junio de 2023

Finalización del estudio (Anticipado)

31 de diciembre de 2023

Fechas de registro del estudio

Enviado por primera vez

8 de agosto de 2017

Primero enviado que cumplió con los criterios de control de calidad

26 de septiembre de 2017

Publicado por primera vez (Actual)

29 de septiembre de 2017

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de octubre de 2022

Última actualización enviada que cumplió con los criterios de control de calidad

10 de octubre de 2022

Última verificación

1 de octubre de 2022

Más información

Términos relacionados con este estudio

Palabras clave

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • STUDY00004220

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

3
Suscribir